• Record revenue of $48.2 million, up 30.7% over prior period
• EBITDA up 60.1% to $8.3 million, with EBITDA margin expansion of 310 basis points
• Net Profit After Tax up 61.7% to $4.7 million

Austco Healthcare Limited has reported record financial results for the first half of the 2026 financial year, with revenue increasing 30.7% to $48.2 million compared to the prior corresponding period. The strong revenue growth was underpinned by the successful integration of recent acquisitions, as well as organic growth in the company's core markets. Australia and New Zealand revenue was up $11.1 million, with the recently acquired G&S Technologies and Onix contributing $9.4 million of that growth. Organic growth in Australia and New Zealand was also strong at 10%. North America recorded robust organic growth of 37%. Software and recurring maintenance revenue increased 9% to $5.0 million.Gross margins improved to 52.2%, up from 51.1% in the prior period, despite the inclusion of the lower-margin G&S business. This, combined with disciplined cost management, resulted in a 60.1% increase in EBITDA to $8.3 million, with EBITDA margins expanding 310 basis points to 17.1%.Net Profit After Tax increased 61.7% to $4.7 million, with basic earnings per share rising to 1.283 cents from 0.808 cents in the prior corresponding period. The company remains debt-free, with a cash balance of $15.2 million at 31 December 2025.Austco's Unfilled Contracted Revenue (UCR) book remained steady at $47.2 million as of 16 February 2026, with software and recurring maintenance revenue comprising 18.5% of the UCR. This highlights the important role that higher-margin recurring revenue will play in driving the company's future growth and success.

Austco Healthcare Ltd has not provided any specific forward-looking financial guidance for the 2026 financial year.